Europe’s life science industry is often discussed as a single market, but the latest 2026 Biotechgate country reports, reviewing 2025 data, paints a more nuanced picture. Across the continent, the sector is shaped by a mix of large, diversified ecosystems, highly capitalized biotech hubs, compact innovation clusters and smaller specialist markets. Taken together, these reports highlight both the depth of Europe’s life science base and the uneven pace of funding, pipeline development and regional concentration.
Europe’s Largest Life Science Ecosystems
The United Kingdom remains one of Europe’s clearest examples of scale. According to the 2026 UK Life Science Trend Analysis, the country is home to 4,665 life science companies, including 1,604 biotechs, 378 medtechs, 272 digital health companies and 478 investors. This breadth makes the UK a useful benchmark for the wider European market. It combines a large biotech base, emerging particularly from Oxford and Cambridge, with a strong investor presence and a broad supporting infrastructure.
Germany offers a similarly large but differently weighted ecosystem. The Germany Life Science Trend Analysis reports 4,240 life science companies, including 1,328 biotechs, 664 medtechs, 208 digital health companies and 222 investors. While the UK stands out for its investor count and clinical-stage pipeline, Germany’s profile underlines the importance of infrastructure, services and medtech within Europe’s life science landscape.
Funding Recovery Remains Uneven Across Europe
Funding trends across the reports suggest that Europe’s recovery remains uneven. In Germany, life science private equity funding declined from USD 1.2bn in 2024 to USD 823m in 2025, while biotech private equity funding fell from USD 727m to USD 645m. However, the picture was not uniformly negative: the report also points to a stronger second half of 2025 for biotech financing, suggesting that capital availability may be improving selectively rather than evenly across the market.
Switzerland provides a useful contrast. Although smaller than the UK or Germany by total company count, Switzerland remains one of Europe’s most capital-intensive life science hubs. The Switzerland Life Science Trend Analysis reports that the country’s life science private equity funding rose from USD 1.4bn in 2024 to USD 1.6bn in 2025, while biotech-specific funding increased from USD 967m to USD 1.1bn.
Switzerland Demonstrates the Power of Regional Clusters
The Swiss data also illustrates how concentrated life science investment can be. Basel and Zurich were the strongest cantonal financing hubs in 2025, with Basel rising from USD 571m in 2024 to USD 632m in 2025, and Zurich increasing from USD 151m to USD 356m. This provides a reminder that national ecosystems are often powered by a small number of highly active regional clusters.
The Netherlands shows another model: a compact, innovation-driven hub. The Netherlands Life Science Trend Analysis reports 1,988 companies across the sector, including 537 biotechs, 173 medtechs, 79 digital health companies and 111 investors. Total Dutch life science venture funding rose from USD 564m in 2024 to USD 676m in 2025, highlighting the country’s continued appeal as a dense and partnership-ready ecosystem.
Oncology Continues to Dominate European Pipelines
Across the country reports, one scientific theme appears repeatedly: oncology remains the dominant clinical focus. In the UK, oncology accounts for 700 biotech assets in clinical development, far ahead of infectiology/parasitology and neurology. Similar oncology-heavy pipelines are visible across Switzerland, Germany, the Netherlands and Norway, showing that while national ecosystems differ in size and funding structure, many are targeting overlapping therapeutic priorities.
Smaller Markets Are Finding Their Niche
Smaller markets add another layer to the European picture. Norway’s 2026 report identifies 538 life science companies and describes an ecosystem built on strong biotech foundations and growing digital health activity. However, Norway also illustrates the financing gap that can exist between smaller and larger European markets. The report shows a much tighter 2025 funding environment than in neighboring Nordic countries, making Norway a useful counterpoint to the larger capital pools seen in Switzerland, the UK and Germany.
Overall, the 2026 European country reports show that Europe’s life science strength lies in its diversity. The UK and Germany provide scale, Switzerland offers capital intensity and regional concentration, the Netherlands demonstrates the power of compact innovation clusters, and Norway highlights the specialist potential – and funding challenges – of smaller markets. For companies, investors and business development teams, this makes Europe less a single market than a connected network of complementary life science ecosystems.